You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 7,470,421


✉ Email this page to a colleague

« Back to Dashboard


Title:Delivery of diazepam through an inhalation route
Abstract: The present invention relates to the delivery of compounds for the treatment of anxiety disorders and symptoms of such disorders through an inhalation route. Specifically, it relates to aerosols containing diazepam that are used in inhalation therapy. In a method aspect of the present invention, diazepam is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of diazepam on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering diazepam through an inhalation route is provided which comprises: a) a thin coating of a diazepam composition; and, b) a device for dispending said thin coating as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D (Princeton, NJ), Zaffaroni; Alejandro C (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc (Mountain View, CA)
Filing Date:Aug 07, 2006
Application Number:11/500,736
Claims:1. A condensation aerosol for delivery of diazepam formed by heating a composition containing diazepam coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of diazepam and less than 5 percent by weight of diazepam degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of less than 3 microns.

3. The condensation aerosol according to claim 1 or claim 2, wherein the geometric standard deviation around the MMAD is less than 3.0.

4. A method of forming a diazepam containing aerosol comprising: a. heating a composition containing diazepam coated on a solid support to form a vapor; and b. condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of diazepam degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

5. The method according to claim 4, wherein the condensation aerosol has an MMAD of less than 3 microns.

6. The method according to claim 5, wherein the coated composition comprises at least 10 percent by weight of diazepam.

7. A method of forming a diazepam containing aerosol comprising: a. heating a composition containing diazepam and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and b. condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of diazepam and less than 5 percent by weight of diazepam degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

8. The method according to claim 7, wherein the condensation aerosol has an MMAD of less than 3 microns.

9. The method according to claim 8, wherein the coated composition comprises at least 10 percent by weight of diazepam.

10. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool.

11. The method according to claim 5, wherein the condensing comprises allowing the vapor to cool.

12. The method according to claim 8, wherein the condensing comprises allowing the vapor to cool.

13. A method of forming a diazepam containing aerosol comprising: (a) heating a composition containing diazepam coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of diazepam and less than 5 percent by weight of diazepam degradation products and the condensation aerosol has an MMAD of less than 5 microns.

14. The method according to claim 13, wherein the condensation aerosol has an MMAD of less than 3 microns.

15. The method according to claim 14, wherein the condensation aerosol is formed at a rate greater than 1 mg/second.

16. The method according to claim 15, wherein the condensation aerosol is formed at a rate greater than 2 mg/second.

17. The method according to claim 14, wherein the condensing comprises allowing the vapor to cool.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.